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1936Objectives: The ability to capture and characterize peripheral blood circulating tumor cells has the potential for
the development of a blood test for cancer. The aim of this study was to evaluate the diagnostic performance of
microfluidic technology as a proof-of-concept study.
Methods: Blood from patients undergoing surgery for known or suspected lung cancer was obtained and
processed using a microfluidic biochip. Diagnostic performance was evaluated against the reference of
cancer identified within surgically obtained formalin-fixed paraffin embedded specimens reported by a principal
pathologist. Agreement was assessed in a sample reported by a second independent pathologist. Sensitivity- and
specificity-weighted analyses were undertaken.
Results: From March 2011 to October 2012, 46 patients at our institution donated blood for research. Cancer
was the underlying diagnosis in 43 (94%); 34 (79%) of the patients had primary lung cancer. The proportion
of patients with cancer in which atypical cells suspicious for cancer were identified on hematoxylin and eosin
staining was 16/43 (37%) by the principal pathologist and 10/17 (59%) by the second pathologist. On
sensitivity-weighted analysis, the sensitivity of the biochip was 54% (95% confidence interval [CI], 37-72)
and the specificity was 33% (95% CI, 2-91). On specificity-weighted analysis, the sensitivity was 43%
(95% CI, 21-71) and the specificity was 100% (95% CI, 5-100).
Conclusions: This work highlights the potential of microfluidic technology to develop a blood test for the
diagnosis of cancer using peripheral blood; conventional clinical criteria can be used as a proof-of-concept of
what may be possible with today’s technology. (J Thorac Cardiovasc Surg 2014;147:1936-8)The ability to capture and characterize circulating tumor
cells (CTCs) has the potential to lead to clinical applications
in cancer that include disease monitoring, refining
prognosis, and predicting treatment response.
Several different technologies are being developed to
capture peripheral blood CTCs either by size filtration,
antibody recognition (followed by immunomagnetic sepa-
ration), or direct blood smear analysis.1 Indirect identifica-
tion of CTCs in peripheral blood by real-time polymerase
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The Journal of Thoracic and Cardiovascular Surmicrofluidic engineering have facilitated the development
of an antibody-independent, microfluidic, biochip designed
to capture peripheral blood CTCs.3 Initial tests developed
using spiked in cancer cells (from cell lines) were
undertaken with good results, however the technology has
yet to be evaluated in a clinical setting.
In this study, the microfluidic biochip was evaluated to
determine if it is possible to capture and identify cancer
cells circulating in the blood of patients using conventional
cytomorphologic criteria with hematoxylin and eosin
(H&E) staining as a proof-of-concept study in a series of
patients undergoing surgery for lung cancer.METHODS
The study was undertaken at The Royal Brompton and Harefield NHS
Foundation Trust. The project was approved under the auspices of the
National Institute of Health Biomedical Research Unit Advanced Disease
Biobank (NRES 10/H0504/9).
From March 2011 to February 2012, blood samples were obtained
from 46 patients and processed using the ClearCell CTChip (Clearbridge
BioMedics, Singapore) by filtering 1 mL of blood within a microfluidic
biochip and trapping cells within the 900 chambers; the samples were
subsequently stained using H&E and reported in-chip3 as previously
described.4 Patient blood samples were acquired before surgery
(by venesection or central venous catheter) and samples were processed
on the day of receipt.
After H&E staining, the biochips were assessed by a principal
pathologist (A.G.N). When present, enlarged nucleated cells, either single
or in clusters, were classified as atypical cells suspicious for cancer.gery c June 2014
Abbreviations and Acronyms
CTC ¼ circulating tumor cell
H&E ¼ hematoxylin and eosin
SD ¼ standard deviation
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blinded fashion independently by a second pathologist. Agreement was
reported by means of a kappa statistic and degree of agreement was
classified according to the criteria of Landis and Koch5: less than 0, no
agreement; 0.0 to 0.20, slight agreement, 0.21 to 0.40, fair agreement;
0.41 to 0.60, moderate agreement; 0.61 to 0.80, substantial agreement;
0.81 to 1.00, almost perfect agreement.
The diagnostic performance of the microfluidic system was evaluated
by sensitivity, specificity, and positive and negative predictive values
against the reference standard of cancer identified within surgically
obtained formalin-fixed paraffin embedded biopsy or resection specimens
of lung. Exploratory analyses were undertaken to help determine the
optimum clinical classification: a sensitivity-weighted analysis (either
pathologist classifies the results as suspicious or positive for cancer) and
a specificity-weighted analysis (both pathologists classify the results as
suspicious or positive for cancer).
Categorical data are presented as frequencies (%) and continuous data
are presented as means with standard deviation (SD). Statistical analyses
were performed using Stata version 10.0 (StataCorp, College Station, Tex).TABLE 1. Baseline characteristics of the patients
Characteristic Value
Sample size, n 46
Mean age, y (SD) 66 (12)
Men, n (%) 22 (48)
Cancer as an underlying diagnosis, n (%) 43 (94)
Primary lung cancer, n (%) 34 (79)
Metastatic lung cancer, n (%) 8 (19)
Other primary thoracic malignancy, n (%) 1 (2)
Benign lung disease, n (%) 3 (6)
Tumor grade
Stage I to II, n (%) 18 (42)
Stage III to IV, n (%) 22 (51)
Insufficient information to classify stage, n (%) 3 (7)
Tumor size
T1, n (%) 13 (30)
T2, n (%) 13 (30)
T3, n (%) 2 (5)
T4, n (%) 5 (12)
Unknown, n (%) 10 (23)
Lymph node status
Positive, n (%) 20 (46)
Negative, n (%) 21 (49)
Unknown, n (%) 2 (5)
Smoking history
Current smoker, n (%) 10 (22)
Ex-smoker, n (%) 16 (35)
Never smoker, n (%) 6 (13)
Unknown, n (%) 14 (30)
SD, Standard deviation.
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From March 2011 to October 2012, 46 patients at our
institution donated blood for research (Table 1). The mean
age was 66 years (SD 12 years) and 22 (48%) were men.
Cancer was present as an underlying diagnosis in 43
(94%); 34 (79%) had primary lung cancer and metastatic
cancer of nonlung origin was diagnosed in 8 (19%). Of
the 43 patients with cancer, 18 (42%) had stage I to II
tumors and 22 (51%) had stage III to IV tumors. In 3 cases,
the stage of the tumor was not identified. The size of 60% of
tumors was category T1 or T2; 46% were lymph node
positive and 49% were lymph node negative.
The proportion of patients with cancer in which atypical
cells suspicious for cancer were identified on H&E staining
was 16/43 (37%) by the principal pathologist and 10/17
(59%) by the second pathologist. Each pathologist also iden-
tified the cells in 1 of the 3 patients with benign disease they
tested. The interobserver agreement was 80% corresponding
to a kappa of 0.615 indicating substantial agreement.
Staging was reported clinically in 40 of 43 patients with
cancer as a diagnosis (Table 1). Among these 40 patients,
atypical cells suspicious for cancer on conventional light
microscopy were identified in 6/18 (33%) patients with
early stage (I/II) and 10/22 (45%) patients with advanced
stage (III/IV) disease.
Using a sensitivity-weighted analysis, the test perfor-
mance for the diagnosis of cancer yielded a sensitivity of
54% (95% confidence interval [CI], 37-72), specificity of
33% (95% CI, 2-91), a negative predictive value of 4%
(95% CI, 1-19), and a positive predictive value of 93%The Journal of Thoracic and Car(95% CI, 89-97). Using a specificity-weighted analysis,
the test performance for the diagnosis of cancer yielded a
sensitivity of 43% (95% CI, 21-71), specificity of 100%
(95% CI, 5-100), a negative predictive value of 7%
(95% CI, 2-29), and a positive predictive value of 95%
(95% CI, 85-98).
DISCUSSION
Microfluidics is considered to be one of the most
promising technologies to capture CTCs.6 The advantage
of microfluidic methods is that they can simultaneously
take into account the physical and biological properties of
CTCs, such as size and expression of tumor-specific
biomarkers. Different microfluidic approaches are being
developed and tested experimentally. This study assessed
the size-filtration technique using a ClearCell CTChip
(Figure 1), which consists of a chamber with 900
crescent-shaped pillar traps that can catch enlarged and
less-deformable (stiffer) tumor cells, while allowing red
blood cells and leukocytes to go through.3 The biological
features of the entrapped cells can be analyzed subsequently
using appropriate staining (including immunocyto-
chemistry); the cells can also be retrieved from the chip
and used for downstream applications such as gene
expression analysis, mutation detection, and cell culture.diovascular Surgery c Volume 147, Number 6 1937
FIGURE 1. Microfluidic biopchip next to a US 10 cent coin.
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technology was used to capture atypical cells from
peripheral blood by staining them using routine histologic
stains and examining them using light microscopy.
Although the clinical test performance was not perfect for
sensitivity, excellent specificity was achieved using 1 mL
of blood for diagnosing lung cancer. The samples analyzed
were collected in a nonbiased prospective way without
preliminary selection of patients by any criteria. Therefore,
we believe that the sample reflects a common situation for
clinicians in daily practice. As a drawback, the sample
contains only 3 patients with benign lung disease, hence
the wide confidence limits with the estimates of specificity.
Currently, a panel of antibody stains (such as EpCAMþ,
CD45, DAPIþ) are commonly applied to diagnose lung
cancer using CTCs. However, this is not the accepted
clinical definition as published by the World Health
Organization7 and epithelial (nonmalignant) cells also carry
the same immunophenotype.8 In an effort to develop a
point-of-care blood-based diagnostic test, our focus is on
replicating conditions that would facilitate conventional
clinical diagnosis from blood; microfluidic technology
seems to provide a (small) advance on current technology
that cannot differentiate epithelial and cancer cell capture.
With regard to potential clinical application, the current
test performance (relatively low sensitivity) suggests that
as a negative result cannot rule out disease, the high
specificity implies that patients who test positive most
likely do have the disease. The test sensitivity is influenced
by the number of patients (with suspected lung cancer) with
CTCs in the blood, a parameter this is not well studied
(and not under our control), and may be affected by the
small amount of blood (1 mL) used. In addition, analysis
and reporting of cells within a microfluidic chamber is a1938 The Journal of Thoracic and Cardiovascular Surcompletely new method of reporting on cells that have
been subject to shear stresses. Based on our data, we
estimate that 33% of patients with early cancer and 45%
of patients with advanced cancer have atypical cells
identifiable in their peripheral blood. If this is the case,
successful clinical implementation could define this as the
proportion of patients who would not need to undergo
confirmatory tissue biopsy. Currently, our estimates
have a wide confidence interval because it was a proof-of-
concept study.
At present, this technology is limited by an inability to
definitively confirm that the atypical cells are from the
primary tumor, but given their morphology, it seems likely
that this is the case as the cells are larger than circulating
lymphocytes and other white blood cells. The shear stress
rendered from the microfluidic cell capture distorts the
architecture of the cells and having to undertake light
microscopy though a biochip is an additional a limitation.
This may be one of the main reasons for disagreement
between the pathologists in identification of the CTCs
(20% in our study). Further refinements are underway to
ensure better cell preservation and complete cell extraction
with the application of immunocytochemistry (where
required) to further characterize the captured cells in our
efforts to achieve a clinical grade diagnostic test.
CONCLUSIONS
Our results demonstrate the potential of microfluidic
technology to develop a highly specific blood test for the
diagnosis of cancer in peripheral blood; conventional
clinical criteria can be used as proof-of-concept of what
can be achieved with today’s technology.
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